GlassScriptPhysician profile
Amy A Rosenbaum
NPI 1821357641
$3,412.05
in general payments reported to CMS, 2019-2025
36 companies · $194 in 2025
The $194 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $521 · 2020: $700 · 2021: $507 · 2022: $516 · 2023: $870 · 2024: $104 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,038 · Education: $94.00 · Gift: $36.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,038.02 |
| Education | $94.00 |
| Gift | $36.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,071.75 | 2019-2025 | |
| Astellas Pharma US INC | $357.60 | 2023-2024 | Veozah, Myrbetriq |
| Daiichi Sankyo INC. | $269.88 | 2019-2024 | Injectafer |
| Caldera Medical, INC | $244.50 | 2020-2023 | Desara |
| Mayne Pharma Commercial LLC | $136.27 | 2022-2025 | |
| Axonics, INC. | $135.93 | 2023 | Axonics, Bulkamid |
| Hologic Sales and Service, LLC | $118.83 | 2019-2025 | Fetal Fibronectin Enzyme Immunoassay |
| Intuitive Surgical, INC. | $114.59 | 2020 | |
| Exeltis, USA INC. | $96.75 | 2021-2023 | Slynd |
| Abbott Laboratories | $86.90 | 2022-2023 | Proclaim |
| Bayer Healthcare Pharmaceuticals INC. | $81.67 | 2019-2023 | |
| Myovant Sciences INC. | $78.97 | 2022 | |
| Sumitomo Pharma America, INC. | $54.25 | 2023-2025 | Myfembree, Gemtesa |
| Pfizer INC. | $47.84 | 2023-2024 | |
| Boston Scientific Corporation | $45.86 | 2022-2024 | Advantage System |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $45.11 | 2023-2025 | |
| Therapeuticsmd, INC. | $42.43 | 2022 | |
| Coopersurgical, INC. | $40.60 | 2020-2022 | |
| Agile Therapeutics, INC. | $34.10 | 2021-2022 | |
| Allergan, INC. | $31.91 | 2021 | |
| Avion Pharmaceuticals | $29.77 | 2021 | |
| Applied Medical Resources Corporation | $25.49 | 2021 | |
| Becton, Dickinson and Company | $21.55 | 2024 | Bd Onclarity |
| Biohaven Pharmaceutical Holding Company LTD. | $21.19 | 2022 | |
| Octapharma USA, INC. | $17.80 | 2025 | Fibryga |
| Evofem Biosciences, INC. | $17.73 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $17.38 | 2022 | |
| Roche Diagnostics Corporation | $17.33 | 2019 | |
| Organon LLC | $16.66 | 2021 | |
| Avanos Medical | $15.02 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.24 | 2020 | |
| Bard Access Systems, INC. | $13.85 | 2019 | |
| Olympus America INC. | $12.92 | 2023 | |
| Lupin INC. | $12.16 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.10 | 2019 | |
| Mallinckrodt Enterprises LLC | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Rosenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.